2. Academic Validation
  3. Recent advances in the development of HBV capsid assembly modulators

Recent advances in the development of HBV capsid assembly modulators

  • Curr Opin Chem Biol. 2019 Jun;50:73-79. doi: 10.1016/j.cbpa.2019.02.009.
Bhavitavya Nijampatnam 1,  Dennis C Liotta 2
Affiliations

Affiliations

  • 1 Department of Chemistry, Emory University, 1515 Dickey Drive NE, Atlanta, GA, 30322, United States.
  • 2 Department of Chemistry, Emory University, 1515 Dickey Drive NE, Atlanta, GA, 30322, United States. Electronic address: dliotta@emory.edu.
PMID: 30952041 DOI: 10.1016/j.cbpa.2019.02.009
Abstract

Hepatitis B virus (HBV) infections represent a significant burden on global public health. Current HBV treatments using nucleos(t)ide analogs (NAs) and PEG interferons cannot fully alleviate this burden as they do not affect the transcriptional activity of the tenacious covalently closed circular DNA (cccDNA) responsible for viral persistence. Capsid assembly modulators (CAMs) disrupt the encapsidation of pre-genomic RNA and can cause nucleocapsid disassembly, thereby affecting multiple steps of HBV replication and reduction of cccDNA pools. This review provides a concise overview of the development of CAMs and the progress achieved in understanding their interactions with HBV core proteins.

Figures
Products
  • Cat. No.
    Product Name
    Description
    Target
    Research Area
  • HY-124614
    98.23%, HBV Capsid Effector
    HBV
嗨！很高兴为您提供帮助！

尊敬的 MCE 客户您好，
请您选择所在区域，我们将转接对应客服为您服务！

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

热 A B C F G H J L N Q S T X Y Z